Allergan Stock Price, News & Analysis (NYSE:AGN)

$164.04 -0.43 (-0.26 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$164.04
Today's Range$162.90 - $165.75
52-Week Range$156.00 - $256.80
Volume2.65 million shs
Average Volume3.21 million shs
Market Capitalization$54.70 billion
P/E Ratio-13.68
Dividend Yield1.76%
Beta1.19

About Allergan (NYSE:AGN)

Allergan logoAllergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drugs - Generic
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:AGN
CUSIP01849010
Phone353-1435-7700

Debt

Debt-to-Equity Ratio0.41%
Current Ratio2.04%
Quick Ratio1.88%

Price-To-Earnings

Trailing P/E Ratio-13.6814011676397
Forward P/E Ratio10.54
P/E Growth1.16

Sales & Book Value

Annual Sales$15.94 billion
Price / Sales3.42
Cash Flow$40.01 per share
Price / Cash4.10
Book Value$222.01 per share
Price / Book0.74

Profitability

Trailing EPS($11.99)
Net Income$-4,125,500,000.00
Net Margins-26.32%
Return on Equity8.28%
Return on Assets4.75%

Miscellaneous

Employees16,700
Outstanding Shares332,580,000

Allergan (NYSE:AGN) Frequently Asked Questions

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan pay dividends? What is the dividend yield for Allergan?

Allergan declared a quarterly dividend on Friday, February 9th. Shareholders of record on Wednesday, February 28th will be given a dividend of $0.72 per share on Wednesday, March 28th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.76%. The ex-dividend date is Tuesday, February 27th. This is a positive change from Allergan's previous quarterly dividend of $0.70. View Allergan's Dividend History.

How will Allergan's stock buyback program work?

Allergan declared that its Board of Directors has approved a share repurchase plan on Tuesday, September 26th 2017, which allows the company to buyback $2,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 2.8% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's board of directors believes its stock is undervalued.

How were Allergan's earnings last quarter?

Allergan plc (NYSE:AGN) released its quarterly earnings results on Tuesday, February, 6th. The company reported $4.86 EPS for the quarter, topping the Zacks' consensus estimate of $4.74 by $0.12. The company had revenue of $4.33 billion for the quarter, compared to analysts' expectations of $4.28 billion. Allergan had a positive return on equity of 8.28% and a negative net margin of 26.32%. The business's quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.90 EPS. View Allergan's Earnings History.

When will Allergan make its next earnings announcement?

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Allergan.

What guidance has Allergan issued on next quarter's earnings?

Allergan updated its FY18 earnings guidance on Tuesday, February, 6th. The company provided EPS guidance of $15.25-16.00 for the period, compared to the Thomson Reuters consensus estimate of $15.42. The company issued revenue guidance of $15.0-15.3 billion, compared to the consensus revenue estimate of $15.25 billion.Allergan also updated its Q1 guidance to $3.20-3.40 EPS.

Where is Allergan's stock going? Where will Allergan's stock price be in 2018?

18 analysts have issued 1 year price targets for Allergan's shares. Their forecasts range from $160.07 to $280.00. On average, they expect Allergan's share price to reach $225.59 in the next year. View Analyst Ratings for Allergan.

What are Wall Street analysts saying about Allergan stock?

Here are some recent quotes from research analysts about Allergan stock:

  • 1. Cantor Fitzgerald analysts commented, "Key takeaways from the quarter: 1) AGN has more important pipeline catalysts in 2018 including those for the CGRPs for migraine, abicipar for AMD, and the FDA approval of Esmya. 2) LOEs and mix will impact AGN’s margins in the near term, but its cost-cutting initiatives will buffer the impact with longer- term margin expansion driven by pipeline success. 3) ~One-third of AGN’s sales comes from cash pay products and Botox Therapeutics, and AGN believes this will grow to ~45% of sales by 2022. 4) Capital allocation strategy is sound with AGN on its way to achieving a 3x leverage ratio, and maintaining its investment grade rating, AGN will be opportunistic on its $2B share buyback and is committed to growing its dividend. 5) As of 12/31/17, AGN had cash & equivalents of $6.5B and debt of $30.1B, CFLO from operations increased to ~$2.1B in 4Q17. 6) Top line results from ACHIEVE I (UBR-MD-01) study demonstrated efficacy, safety and tolerability, study met co-primary endpoints in the first of two Phase 3 studies, there were 6 cases with aminotransferase (ALT or AST) elevations greater than 3x the upper limit of normal, and there were alternative explanations in all cases." (2/6/2018)
  • 2. According to Zacks Investment Research, "Allergan’s products like Botox and Linzess and new products such as Viberzi, Namzaric and Vraylar support sales. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, while we remain optimistic about the company’s growth prospects, it is facing potential loss of exclusivity for many products in 2018 including Namenda XR and Restasis. In October 2017, a Texas federal district court invalidated four of the six patents covering Restasis, potentially opening doors for early generic competition. Though Restasis patents are scheduled to expire in August 2024, a generic version may be launched as early as mid-2018. Also, new competition for key growth drivers, Restasis and Linzess, is an investor concern. Allergan’s shares underperformed the industry in the past six months. " (1/2/2018)

Who are some of Allergan's key competitors?

Who owns Allergan stock?

Allergan's stock is owned by many different of retail and institutional investors. Top institutional investors include Clearbridge Investments LLC (2.37%), Geode Capital Management LLC (1.03%), Bank of New York Mellon Corp (1.00%), Parnassus Investments CA (0.65%), UBS Asset Management Americas Inc. (0.53%) and Iridian Asset Management LLC CT (0.51%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Maria Teresa Hilado, Nesli Basgoz, Paul Bisaro and William Meury. View Institutional Ownership Trends for Allergan.

Who sold Allergan stock? Who is selling Allergan stock?

Allergan's stock was sold by a variety of institutional investors in the last quarter, including TIAA CREF Investment Management LLC, Eaton Vance Management, Lazard Asset Management LLC, Virtus Fund Advisers LLC, Clearbridge Investments LLC, Public Employees Retirement Association of Colorado, MD Sass Investors Services Inc. and DAVENPORT & Co LLC. Company insiders that have sold Allergan company stock in the last year include Nesli Basgoz, Paul Bisaro and William Meury. View Insider Buying and Selling for Allergan.

Who bought Allergan stock? Who is buying Allergan stock?

Allergan's stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Millennium Management LLC, Swedbank, Two Sigma Advisers LP, Polaris Capital Management LLC, Parnassus Investments CA, HL Financial Services LLC and Canyon Capital Advisors LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin and Maria Teresa Hilado. View Insider Buying and Selling for Allergan.

How do I buy Allergan stock?

Shares of Allergan can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allergan's stock price today?

One share of Allergan stock can currently be purchased for approximately $164.04.

How big of a company is Allergan?

Allergan has a market capitalization of $54.70 billion and generates $15.94 billion in revenue each year. The company earns $-4,125,500,000.00 in net income (profit) each year or ($11.99) on an earnings per share basis. Allergan employs 16,700 workers across the globe.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 353-1435-7700 or via email at [email protected]


MarketBeat Community Rating for Allergan (AGN)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  963 (Vote Outperform)
Underperform Votes:  435 (Vote Underperform)
Total Votes:  1,398
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Allergan (NYSE:AGN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.592.582.72
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $225.59$225.60$245.00$277.76
Price Target Upside: 32.03% upside29.83% upside38.24% upside19.27% upside

Allergan (NYSE:AGN) Consensus Price Target History

Price Target History for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/7/2018Credit Suisse GroupBoost Price TargetOutperform -> Outperform$214.00 -> $215.00LowView Rating Details
2/7/2018Bank of AmericaBoost Price TargetBuy -> Buy$208.00 -> $215.00LowView Rating Details
2/7/2018Leerink SwannBoost Price TargetOutperform -> Outperform$237.00 -> $242.00LowView Rating Details
2/6/2018Cantor FitzgeraldReiterated RatingHold$191.00LowView Rating Details
1/29/2018BarclaysUpgradeEqual Weight -> Overweight$220.00 -> $230.00LowView Rating Details
1/24/2018Morgan StanleyReiterated RatingBuyLowView Rating Details
1/9/2018Deutsche BankReiterated RatingBuy$215.00MediumView Rating Details
1/9/2018CitigroupLower Price TargetBuy$215.00N/AView Rating Details
1/5/2018Wells Fargo & CoSet Price TargetBuy$245.00LowView Rating Details
1/4/2018Royal Bank of CanadaSet Price TargetBuy$218.00LowView Rating Details
12/7/2017ArgusDowngradeBuy -> Hold$256.80 -> $160.07LowView Rating Details
10/22/2017JPMorgan Chase & Co.Set Price TargetBuy$275.00N/AView Rating Details
10/20/2017CowenSet Price TargetBuy$400.00 -> $280.00N/AView Rating Details
10/19/2017MizuhoDowngradeBuy -> Neutral$193.00 -> $193.00N/AView Rating Details
10/18/2017Edward JonesReiterated RatingBuy -> HoldN/AView Rating Details
10/18/2017Sanford C. BernsteinSet Price TargetBuy$296.00 -> $252.00N/AView Rating Details
10/13/2017Piper Jaffray CompaniesSet Price TargetHold$227.00N/AView Rating Details
5/10/2017Goldman Sachs GroupDowngradeBuy -> Neutral$262.00HighView Rating Details
11/21/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
4/18/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
4/7/2016Raymond James FinancialLower Price TargetOutperform$317.00 -> $275.00N/AView Rating Details
4/7/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
4/7/2016Susquehanna BancsharesDowngradePositive -> Neutral$345.00 -> $275.00N/AView Rating Details
4/5/2016NomuraReiterated RatingBuy$350.00 -> $330.00N/AView Rating Details
(Data available from 2/17/2016 forward)

Earnings

Allergan (NYSE:AGN) Earnings History and Estimates Chart

Earnings by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE AGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018$3.39N/AView Earnings Details
2/6/2018Q4 2017$4.74$4.86$4.28 billion$4.33 billionViewListenView Earnings Details
11/1/2017Q3 2017$4.06$4.15$4.04 billion$4.03 billionViewN/AView Earnings Details
8/3/2017Q2 2017$3.95$4.02$3.95 billion$4.01 billionViewListenView Earnings Details
5/9/2017Q1 2017$3.32$3.35$3.53 billion$3.57 billionViewListenView Earnings Details
2/8/2017Q416$3.76$3.90$3.77 billion$3.86 billionViewListenView Earnings Details
11/2/2016Q316$3.57$3.32$3.73 billion$3.62 billionViewListenView Earnings Details
8/8/2016Q216$3.34$3.35$4.10 billion$3.68 billionViewListenView Earnings Details
5/10/2016Q116$3.03$3.04$3.97 billion$3.80 billionViewListenView Earnings Details
2/22/2016Q415$3.36$3.41$4.20 billion$4.20 billionViewListenView Earnings Details
11/4/2015Q315$3.20$3.48$5.71 billion$4.10 billionViewN/AView Earnings Details
8/6/2015Q215$4.41$4.41$5.71 billion$5.76 billionViewN/AView Earnings Details
5/11/2015Q115$3.84$4.30$4.04 billion$4.23 billionViewListenView Earnings Details
2/18/2015Q414$3.67$3.91$3.84 billion$4.01 billionViewN/AView Earnings Details
11/5/2014Q414$1.83$2.17$1.90 billion$1.91 billionViewN/AView Earnings Details
11/5/2014Q314$3.10$3.19$3.63 billion$3.68 billionViewN/AView Earnings Details
8/5/2014Q314$1.76$1.78$1.78 billion$1.79 billionViewListenView Earnings Details
8/5/2014Q214$3.36$3.42$2.55 billion$2.67 billionViewN/AView Earnings Details
7/21/2014Q214$1.44$1.51$1.77 billion$1.83 billionViewN/AView Earnings Details
4/30/2014Q114$1.13$1.18$1.60 billion$1.65 billionViewN/AView Earnings Details
4/30/2014Q114$3.23$3.49$2.59 billion$2.66 billionViewListenView Earnings Details
2/20/2014Q413$3.05$3.17$2.68 billion$2.78 billionViewListenView Earnings Details
2/4/2014Q413$1.34$1.12$1.65 million$1.66 millionViewN/AView Earnings Details
10/29/2013Q313$1.20$1.23$1.53 billion$1.23 billionViewListenView Earnings Details
10/29/2013Q313$2.09$2.09$2.04 billion$2.01 billionViewListenView Earnings Details
7/31/2013Q2 2013$1.20$1.22$1.56 billion$1.60 billionViewN/AView Earnings Details
7/25/2013Q2 2013$2.00$2.01$1.99 billion$1.99 billionViewListenView Earnings Details
5/2/2013Q1 2013$1.86$1.99$1.97 billion$1.90 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.96$0.98$1.44 billion$1.46 billionViewN/AView Earnings Details
2/19/2013Q4 2012$1.53$1.59$1.74 million$1.75 billionViewListenView Earnings Details
2/5/2013Q4 2012$1.20$1.15$1.51 million$1.48 millionViewN/AView Earnings Details
10/30/2012Q312$1.04$1.06$1.43 billion$1.39 billionViewN/AView Earnings Details
8/1/2012$1.06$1.07ViewN/AView Earnings Details
5/2/2012$0.87$0.86ViewN/AView Earnings Details
2/14/2012Q4 2011$1.75$1.77ViewN/AView Earnings Details
2/2/2012$1.00$1.00ViewN/AView Earnings Details
10/26/2011$0.90$0.92ViewN/AView Earnings Details
8/3/2011$0.95$0.96ViewN/AView Earnings Details
7/26/2011Q2 2011$1.00$1.01ViewN/AView Earnings Details
5/4/2011$0.74$0.77ViewN/AView Earnings Details
2/15/2011Q4 2010$0.93$0.93ViewN/AView Earnings Details
2/2/2011$0.89$0.88ViewN/AView Earnings Details
11/4/2010Q3 2010$0.84$0.85ViewN/AView Earnings Details
8/5/2010Q2 2010$0.81$0.83ViewN/AView Earnings Details
5/10/2010Q1 2010$0.74$0.63ViewN/AView Earnings Details
2/23/2010Q4 2009$0.72$0.85ViewN/AView Earnings Details
11/4/2009Q3 2009$0.65$0.66ViewN/AView Earnings Details
7/29/2009Q2 2009$0.57$0.61ViewN/AView Earnings Details
4/30/2009Q1 2009$0.49$0.58ViewN/AView Earnings Details
2/19/2009Q4 2008$0.50$0.53ViewN/AView Earnings Details
10/29/2008Q3 2008$0.46$0.48ViewN/AView Earnings Details
8/6/2008Q2 2008$0.48$0.48ViewN/AView Earnings Details
5/1/2008Q1 2008$0.51$0.55ViewN/AView Earnings Details
2/20/2008Q4 2007$0.31$0.35ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Allergan (NYSE:AGN) Earnings Estimates

2018 EPS Consensus Estimate: $15.46
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$3.37$3.83$3.60
Q2 20182$3.17$3.91$3.54
Q3 20182$3.86$3.86$3.86
Q4 20182$4.10$4.81$4.46
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Allergan (NYSE:AGN) Dividend Information

Next Dividend:3/28/2018
Annual Dividend:$2.80
Dividend Yield:1.71%
Dividend Growth:141.00% (3 Year Average)
Payout Ratio:-23.35% (Trailing 12 Months of Earnings)
17.98% (Based on This Year's Estimates)
16.93% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/9/2018quarterly$0.720.00438489646772229%2/27/20182/28/20183/28/2018
10/27/2017quarterly$0.701.58%11/16/201711/17/201712/15/2017
8/2/2017Quarterly$0.701.12%8/16/20178/18/20179/15/2017
5/5/2017quarterly$0.700.01%5/16/20175/18/20176/15/2017
11/2/2016quarterly$0.702/24/20172/28/20173/28/2017
2/4/2015quarterly$0.050.09%2/5/20152/9/20153/20/2015
10/27/2014quarterly$0.0511/20/201412/11/2014
7/28/2014quarterly$0.050.12%8/13/20148/15/20149/5/2014
5/7/2014quarterly$0.050.12%5/21/20145/23/20146/13/2014
2/5/2014quarterly$0.050.17%2/26/20142/28/20143/21/2014
10/30/2013quarterly$0.050.22%11/18/201311/20/201312/11/2013
7/31/2013quarterly$0.050.22%8/20/20138/22/20139/12/2013
5/2/2013quarterly$0.050.2%5/21/20135/23/20136/13/2013
2/6/2013quarterly$0.050.18%2/26/20132/28/20133/21/2013
(Data available from 1/1/2013 forward)

Insider Trades

Allergan (NYSE AGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.36%
Institutional Ownership Percentage: 79.76%
Insider Trades by Quarter for Allergan (NYSE:AGN)
Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE AGN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/14/2018William MeuryInsiderSell58,879$160.62$9,457,144.98View SEC Filing  
12/7/2017Chris W. BodineDirectorBuy3,030$164.77$499,253.10View SEC Filing  
12/6/2017Brent L. SaundersChairmanBuy4,600$164.74$757,804.00View SEC Filing  
12/5/2017Christopher J. CoughlinDirectorBuy10,000$163.30$1,633,000.00View SEC Filing  
12/1/2017William MeuryInsiderSell11,807$173.89$2,053,119.23View SEC Filing  
5/18/2017Nesli BasgozDirectorSell1,889$220.45$416,430.05View SEC Filing  
3/2/2017Paul BisaroDirectorSell70,000$246.68$17,267,600.00274,226View SEC Filing  
12/8/2016Nesli BasgozDirectorSell500$188.72$94,360.00View SEC Filing  
11/21/2016Brent L. SaundersCEOBuy5,250$189.13$992,932.50View SEC Filing  
11/11/2016Maria Teresa HiladoCFOBuy1,422$210.64$299,530.0812,659View SEC Filing  
6/2/2016Maria Teresa HiladoCFOBuy661$241.57$159,677.7711,957View SEC Filing  
5/11/2016Nesli BasgozDirectorSell459$225.10$103,320.905,242View SEC Filing  
12/7/2015Nesli BasgozDirectorSell2,300$312.96$719,808.004,062View SEC Filing  
8/24/2015Paul BisaroChairmanBuy1,000$297.42$297,420.00421,755View SEC Filing  
8/21/2015Brent L SaundersCEOBuy1,000$301.94$301,940.00132,862View SEC Filing  
6/9/2015Nesli BasgozDirectorSell2,200$297.89$655,358.00View SEC Filing  
11/26/2014William MeuryInsiderSell4,550$269.14$1,224,587.00View SEC Filing  
9/8/2014Albert Paonessa IIIInsiderSell6,642$230.49$1,530,914.58View SEC Filing  
4/22/2014Scott ShermanEVPSell14,500$155.82$2,259,390.008,223View SEC Filing  
2/21/2014Louis Lavigne, Jr.DirectorSell5,400$125.79$679,266.0012,723View SEC Filing  
2/19/2014Dawn HudsonDirectorSell4,200$126.35$530,670.0011,600View SEC Filing  
2/19/2014Jeffrey EdwardsCFOSell38,900$126.39$4,916,571.0016,591View SEC Filing  
2/19/2014Raymond DiradoorianEVPSell23,000$126.66$2,913,180.006,401View SEC Filing  
2/18/2014Scott ShermanEVPSell5,001$125.74$628,825.748,220View SEC Filing  
1/14/2014Scott WhitcupVPSell42,000$117.80$4,947,600.0017,327View SEC Filing  
12/27/2013Julian GangolliVPSell52,500$110.05$5,777,625.00View SEC Filing  
12/20/2013Scott WhitcupVPSell33,000$108.80$3,590,400.0017,327View SEC Filing  
10/15/2013Trevor JonesDirectorSell2,000$90.14$180,280.007,142View SEC Filing  
9/16/2013Albert HummelDirectorSell6,200$137.81$854,422.0082,776View SEC Filing  
9/16/2013Trevor JonesDirectorSell2,000$89.78$179,560.008,142View SEC Filing  
9/4/2013George Fred WilkinsonInsiderSell16,749$138.00$2,311,362.00View SEC Filing  
9/4/2013Jack MichelsonDirectorSell6,064$139.54$846,170.56View SEC Filing  
8/29/2013David BuchenInsiderSell10,000$135.56$1,355,600.0097,373View SEC Filing  
8/26/2013Albert HummelDirectorSell40,000$134.44$5,377,600.0092,776View SEC Filing  
8/20/2013Paul BisaroCEOSell50,000$135.30$6,765,000.00469,232View SEC Filing  
8/15/2013Albert Paonessa IIIInsiderSell5,476$135.89$744,133.6433,812View SEC Filing  
8/15/2013Trevor JonesDirectorSell2,000$89.89$179,780.009,142View SEC Filing  
8/14/2013R Todd JoyceCFOSell15,000$137.98$2,069,700.0080,470View SEC Filing  
8/13/2013Albert HummelDirectorSell10,000$133.85$1,338,500.00132,776View SEC Filing  
8/12/2013Cathy KlemaDirectorSell1,667$133.03$221,761.0119,608View SEC Filing  
8/12/2013David BuchenInsiderSell17,000$133.03$2,261,510.0097,373View SEC Filing  
8/9/2013Ronald TaylorDirectorSell5,000$135.14$675,700.0027,942View SEC Filing  
8/6/2013Jeffrey EdwardsCFOSell69,200$91.17$6,308,964.0016,871View SEC Filing  
8/5/2013Charles EbertVPSell8,244$136.25$1,123,245.0019,970View SEC Filing  
8/5/2013Michel FeldmanDirectorSell10,000$136.94$1,369,400.0012,941View SEC Filing  
8/2/2013Robert StewartInsiderSell14,564$136.02$1,980,995.2873,891View SEC Filing  
7/15/2013Trevor M JonesDirectorSell2,000$91.15$182,300.00View SEC Filing  
6/17/2013Trevor M JonesDirectorSell2,000$101.25$202,500.00View SEC Filing  
5/15/2013Trevor M JonesDirectorSell2,000$103.40$206,800.00View SEC Filing  
5/9/2013Jeffrey L EdwardsCFOSell84,000$103.49$8,693,160.00View SEC Filing  
3/14/2013Charles M MayrInsiderSell1,000$91.77$91,770.00View SEC Filing  
3/12/2013Michael J FedidaDirectorSell8,000$89.00$712,000.00View SEC Filing  
11/26/2012Trevor M JonesDirectorSell2,500$91.30$228,250.00View SEC Filing  
10/5/2012David E I PyottCEOSell616,300$93.73$57,765,799.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Allergan (NYSE AGN) News Headlines

Source:
DateHeadline
Allergan PLC (AGN) Files 10-K for the Fiscal Year Ended on December 31, 2017Allergan PLC (AGN) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 17 at 9:51 AM
Allergan Presents Data at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San DiegoAllergan Presents Data at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego
finance.yahoo.com - February 17 at 9:51 AM
William Meury Sells 58,879 Shares of Allergan plc (AGN) StockWilliam Meury Sells 58,879 Shares of Allergan plc (AGN) Stock
www.americanbankingnews.com - February 16 at 9:12 PM
$3.36 Earnings Per Share Expected for Allergan plc (AGN) This Quarter$3.36 Earnings Per Share Expected for Allergan plc (AGN) This Quarter
www.americanbankingnews.com - February 16 at 7:22 PM
Allergan: Will Growth Come To A Screeching Halt? - Seeking AlphaAllergan: Will Growth Come To A Screeching Halt? - Seeking Alpha
seekingalpha.com - February 16 at 3:36 PM
United Therapeutics reaches patent settlement with ActavisUnited Therapeutics reaches patent settlement with Actavis
finance.yahoo.com - February 16 at 3:36 PM
United Therapeutics settles patent litigation over $157M drugUnited Therapeutics settles patent litigation over $157M drug
finance.yahoo.com - February 16 at 3:36 PM
How Pfizer’s Peri-LOE Products Performed in 2017How Pfizer’s Peri-LOE Products Performed in 2017
finance.yahoo.com - February 15 at 3:38 PM
Allergan Exec on Medical Aesthetics: The Future Is About Market ExpansionAllergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'
finance.yahoo.com - February 15 at 3:38 PM
US stocks keep gaining as tech, industrial companies riseUS stocks keep gaining as tech, industrial companies rise
marketbeat.com - February 15 at 3:12 PM
Jerome Dodson Comments on AllerganJerome Dodson Comments on Allergan
finance.yahoo.com - February 14 at 5:31 AM
Jerome Dodsons Parnassus Fund 4th Quarter CommentaryJerome Dodson's Parnassus Fund 4th Quarter Commentary
finance.yahoo.com - February 14 at 5:31 AM
Notable Tuesday Option Activity: TRIP, SEE, AGN - NasdaqNotable Tuesday Option Activity: TRIP, SEE, AGN - Nasdaq
www.nasdaq.com - February 13 at 3:17 PM
Allergan Mandatory Convertible Preferred Shares, Series A Ex-Dividend Reminder - NasdaqAllergan Mandatory Convertible Preferred Shares, Series A Ex-Dividend Reminder - Nasdaq
www.nasdaq.com - February 12 at 3:16 PM
Allergan Declares First Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share and Provides Annual General Meeting of Shareholders UpdatesAllergan Declares First Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share and Provides Annual General Meeting of Shareholders Updates
finance.yahoo.com - February 10 at 3:20 PM
OxyContin maker will stop promoting opioids to doctorsOxyContin maker will stop promoting opioids to doctors
finance.yahoo.com - February 10 at 3:20 PM
Allergan: Right On Schedule - Seeking AlphaAllergan: Right On Schedule - Seeking Alpha
seekingalpha.com - February 10 at 5:36 AM
Allergan: Be Brave And Buy This Underappreciated Stock - Seeking AlphaAllergan: Be Brave And Buy This Underappreciated Stock - Seeking Alpha
seekingalpha.com - February 10 at 5:36 AM
FY2021 EPS Estimates for Allergan plc Raised by Analyst (AGN)FY2021 EPS Estimates for Allergan plc Raised by Analyst (AGN)
www.americanbankingnews.com - February 9 at 6:14 PM
Teva (TEVA) Q4 Earnings Top, Stock Tanks on Weak 2018 ViewTeva (TEVA) Q4 Earnings Top, Stock Tanks on Weak 2018 View
finance.yahoo.com - February 9 at 3:23 PM
Allergan plc to Post FY2018 Earnings of $15.90 Per Share, Cantor Fitzgerald Forecasts (AGN)Allergan plc to Post FY2018 Earnings of $15.90 Per Share, Cantor Fitzgerald Forecasts (AGN)
www.americanbankingnews.com - February 9 at 1:43 PM
Allergan plc (AGN) Increases Dividend to $0.72 Per ShareAllergan plc (AGN) Increases Dividend to $0.72 Per Share
www.americanbankingnews.com - February 9 at 12:16 PM
Analysts Issue Forecasts for Allergan plcs Q2 2018 Earnings (AGN)Analysts Issue Forecasts for Allergan plc's Q2 2018 Earnings (AGN)
www.americanbankingnews.com - February 9 at 10:58 AM
Allergan plc to Post Q2 2018 Earnings of $3.91 Per Share, Leerink Swann Forecasts (AGN)Allergan plc to Post Q2 2018 Earnings of $3.91 Per Share, Leerink Swann Forecasts (AGN)
www.americanbankingnews.com - February 9 at 10:54 AM
FY2022 EPS Estimates for Allergan plc Raised by Gabelli (AGN)FY2022 EPS Estimates for Allergan plc Raised by Gabelli (AGN)
www.americanbankingnews.com - February 8 at 5:52 PM
The Alzheimers Drug Pipeline: High Failure Rates In Research On An Increasingly Common DiseaseThe Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease
finance.yahoo.com - February 8 at 3:16 PM
Allergan plc (AGN) Forecasted to Post Q1 2018 Earnings of $3.37 Per ShareAllergan plc (AGN) Forecasted to Post Q1 2018 Earnings of $3.37 Per Share
www.americanbankingnews.com - February 8 at 9:52 AM
Leerink Swann Research Analysts Increase Earnings Estimates for Allergan plc (AGN)Leerink Swann Research Analysts Increase Earnings Estimates for Allergan plc (AGN)
www.americanbankingnews.com - February 8 at 9:52 AM
Allergan: Still No Triggers, Soft 2018 Ahead - Allergan plc (NYSE ... - Seeking AlphaAllergan: Still No Triggers, Soft 2018 Ahead - Allergan plc (NYSE ... - Seeking Alpha
seekingalpha.com - February 8 at 5:15 AM
Array BioPharma and Allergan Just Scored Big On Phase III DataArray BioPharma and Allergan Just Scored Big On Phase III Data
finance.yahoo.com - February 8 at 5:15 AM
Allergan (AGN) Price Target Increased to $242.00 by Analysts at Leerink SwannAllergan (AGN) Price Target Increased to $242.00 by Analysts at Leerink Swann
www.americanbankingnews.com - February 7 at 10:26 AM
Allergan Plc (AGN) Q4 2017 Results - Earnings Call Transcript - Seeking AlphaAllergan Plc (AGN) Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 7 at 5:35 AM
Cantor Fitzgerald Reiterates "Hold" Rating for Allergan (AGN)Cantor Fitzgerald Reiterates "Hold" Rating for Allergan (AGN)
www.americanbankingnews.com - February 6 at 4:06 PM
Allergan shares surge after positive late-stage migraine drug results - MarketWatchAllergan shares surge after positive late-stage migraine drug results - MarketWatch
www.marketwatch.com - February 6 at 3:17 PM
Patent Losses Could Sink Allergan - Seeking AlphaPatent Losses Could Sink Allergan - Seeking Alpha
seekingalpha.com - February 6 at 3:17 PM
Allergan CEO: We Are Staying in IrelandAllergan CEO: We Are Staying in Ireland
finance.yahoo.com - February 6 at 3:16 PM
Allergan Pops On Consensus-Topping Quarter, Strong Migraine TrialAllergan Pops On Consensus-Topping Quarter, Strong Migraine Trial
finance.yahoo.com - February 6 at 3:16 PM
Allergan (AGN) Q4 Earnings Beat on Increase in Botox SalesAllergan (AGN) Q4 Earnings Beat on Increase in Botox Sales
finance.yahoo.com - February 6 at 3:16 PM
Dow Explodes With Gain of Nearly 500 Points in Late Afternoon Trading MayhemDow Explodes With Gain of Nearly 500 Points in Late Afternoon Trading Mayhem
finance.yahoo.com - February 6 at 3:16 PM
Allergan (AGN) Updates FY18 Earnings GuidanceAllergan (AGN) Updates FY18 Earnings Guidance
www.americanbankingnews.com - February 6 at 9:14 AM
Allergan (AGN) Issues Q1 Earnings GuidanceAllergan (AGN) Issues Q1 Earnings Guidance
www.americanbankingnews.com - February 6 at 8:50 AM
Allergan (AGN) Announces  Earnings Results, Beats Expectations By $0.12 EPSAllergan (AGN) Announces Earnings Results, Beats Expectations By $0.12 EPS
www.americanbankingnews.com - February 6 at 8:50 AM
Allergans late-stage success with migraine candidate pressures Teva, down 2% premarketAllergan's late-stage success with migraine candidate pressures Teva, down 2% premarket
seekingalpha.com - February 6 at 8:04 AM
Allergan smashes earnings estimates, says a trial for its migraine drug succeedsAllergan smashes earnings estimates, says a trial for its migraine drug succeeds
www.cnbc.com - February 6 at 7:11 AM
Allergans Pipeline Matters More Than Its Earnings Do: RBCAllergan's Pipeline Matters More Than Its Earnings Do: RBC
finance.yahoo.com - February 6 at 5:25 AM
Allergans Pipeline Matters More Than Its Earnings Do: RBC - TheStreet.comAllergan's Pipeline Matters More Than Its Earnings Do: RBC - TheStreet.com
www.thestreet.com - February 5 at 3:16 PM
Allergan names current Catalent CFO as its CFO - MarketWatchAllergan names current Catalent CFO as its CFO - MarketWatch
www.marketwatch.com - February 5 at 3:16 PM
Allergan almost there with restructuring, sees $500M in China sales by 2022 - Seeking AlphaAllergan almost there with restructuring, sees $500M in China sales by 2022 - Seeking Alpha
seekingalpha.com - February 3 at 5:31 AM
Allergan plc (AGN) Given Consensus Recommendation of "Buy" by BrokeragesAllergan plc (AGN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 3 at 3:44 AM
Allergans Anti-Infective Drug Avycaz Receives Third FDA Nod - NasdaqAllergan's Anti-Infective Drug Avycaz Receives Third FDA Nod - Nasdaq
www.nasdaq.com - February 2 at 3:17 PM

SEC Filings

Allergan (NYSE:AGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Allergan (NYSE:AGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Allergan (NYSE AGN) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.